Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Dobutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dobutamine SCHEMBL28350248 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL21237 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL29929447 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Levdobutamine SCHEMBL29387828 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL21238 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL31681391 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL30094854 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL9169324 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL41609 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL10816573 | 0.99 | LMNA (0.97) | LMNAADRB2KDM4EMAPK1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025265094-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2024107708-A1 | TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION | ReJoy (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11337937-B2 | TARR receptor agonists for sexual dysfunction | JOHN MCCOY | 2022-05-24 | — | — | US | disclosed |